Nevro Corp NVRO

NYS: NVRO | ISIN: US64157F1030   31/05/2024
9,350 USD (+1,96%)
(+1,96%)   31/05/2024

24 mei 2024 · Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 · Persbericht

9 mei 2024 · Nevro to Present at BofA Securities 2024 Healthcare Conference · Persbericht

7 mei 2024 · Nevro Reports First-Quarter 2024 Financial Results · Persbericht

17 april 2024 · Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024 · Persbericht

28 februari 2024 · Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw · Persbericht

21 februari 2024 · Nevro Enters Into Cooperation Agreement With Engaged Capital · Persbericht

21 februari 2024 · Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results · Persbericht

1 februari 2024 · Nevro Announces Consensus Statement Supporting High-Frequency (10 kHz) Spinal Cord Stimulation Therapy for Refractory Painful Diabetic Neuropathy · Persbericht

29 januari 2024 · Nevro to Report Fourth-Quarter and Full-Year 2023 Financial Results and Host Conference Call on February 21, 2024 · Persbericht

18 januari 2024 · Nevro Announces Positive Coverage Update from Carelon Healthcare for the Treatment of Painful Diabetic Neuropathy · Persbericht

17 januari 2024 · Nevro to Highlight 25 Scientific Abstracts at 2024 North American Neuromodulation Society (NANS) Annual Meeting · Persbericht

9 januari 2024 · Nevro Announces Preliminary Fourth-Quarter and Full-Year 2023 Revenue Results · Persbericht

4 januari 2024 · Nevro to Present at 42nd Annual J.P. Morgan Healthcare Conference · Persbericht

1 november 2023 · Nevro Reports Third Quarter 2023 Financial Results, Provides Fourth Quarter Guidance and Updates Full-Year 2023 Guidance · Persbericht

4 oktober 2023 · Nevro to Report Third Quarter 2023 Financial Results · Persbericht

18 september 2023 · New Data Demonstrate the Health Economic Benefits of Nevro's High-Frequency Spinal Cord Stimulation Therapy · Persbericht

23 augustus 2023 · Nevro Announces Participation in Upcoming Investor Conferences · Persbericht

16 augustus 2023 · New 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic Neuropathy · Persbericht

1 augustus 2023 · Nevro Reports Second Quarter 2023 Financial Results, Provides Third Quarter Guidance and Updates Full-Year 2023 Guidance · Persbericht

13 juli 2023 · Nevro Announces Presentations at American Society of Pain & Neuroscience Fifth Annual Conference · Persbericht

Mijn selecties